GlobeNewswire Inc | Nov 24, 2020 09:35AM EST

November 24, 2020

JERSEY CITY, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the Companys participation in Piper Sandlers 32nd Annual Virtual Healthcare Conference. Presentations will be available for registered attendees via the Piper Sandler conference site from November 23 to December 3, 2020. The Company will also participate in a panel discussion at Evercore ISIs 3rd Annual HealthCONx Conference taking place on December 2, 2020.

Presentation details

Piper Sandler 32^nd Annual Virtual Healthcare Conference:Presentation Date: Monday, November 23 to Thursday, December 3, 2020Presentation Time: 8:00 a.m. ? 5:00 p.m. ETWebcast: Link

Evercore ISI 3^rd Annual HealthCONx Conference:Panel Discussion No Fungus Among Us: Addressing an Important Need withTopic: Cidara, F2G, and SCYNEXISPresentation Date: Wednesday, December 2, 2020Presentation Time: 11:20 a.m. ? 12:05 p.m. ET

A webcast of both presentation recordings will be available for 30 days and can be found on the Scynexis website at: https://www.scynexis.com/news-media/events.

AboutSCYNEXISSCYNEXIS, Inc.(NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to potentially help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. Our lead candidate,ibrexafungerp (formerly known as SCY-078), is a broad-spectrum, IV/oral antifungal agent representing a novel therapeutic class, in late stage development for multiple indications, ranging from vaginal yeast infections to life-threatening fungal infections in hospitalized patients. The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization. For more information, visitwww.scynexis.com.

CONTACTInvestor RelationsIrina KofflerLifeSci AdvisorsTel: (646) 970-4681ikoffler@lifesciadvisors.com

Media RelationsGloria GasaaturaLifeSci CommunicationsTel: (646) 970-4688ggasaatura@lifescicomms.com